Supervised Injectable Opioid Agonist Treatment

02/13/2026

Presented at HAT expert meeting January 28-29, Oslo, Norway.

https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/maps.html

02/12/2026

Presented at HAT expert meeting January 28-29, Oslo, Norway. Some countries have oral, injectable, intranasal & inhalable formulations.

02/11/2026

Expanding access to take-home HAT aligns with human rights-based healthcare and uplifts economic, social, and cultural rights of people who need this care. Inclusive of oral, injectable, intranasal and inhalable formulations. Presented at HAT expert meeting January 28-29, Oslo, Norway.

02/03/2026

Supervised injectable opioid agonist treatment is established as standard care and one aspect of a comprehensive treatment framework. From Professor Wim van den Brink presentation at Heroin-assisted treatment expert meeting January 28-29, Oslo, Norway.

02/02/2026

Appreciative of the chance to participate in Heroin-assisted treatment expert meeting January 28-29, Oslo, Norway

11/14/2025

"Health Canada ignored expert advice to expand access to safe drugs for opioid users, internal documents show"

As deadly drug overdoses climbed across Canada, decision-makers faced political backlash for funding programs that gave drug users prescribed opioids and, against their own experts’ advice, scaled back their support of safe supply programs, an investigation by CBC’s the fifth estate has found.

11/14/2025

Great work! "Canada's overdose crisis is driven by prohibition, and an illegal market"

Canada’s opioid crisis has led to the deaths of tens of thousands of people, costing the health and justice systems billions. Many health providers say ther...

11/02/2025

https://pmc.ncbi.nlm.nih.gov/articles/PMC12542192/

Furthermore, all centres prescribed take-home DAM...

Conclusions
Swiss HAT is overall easily accessible, patient-centred and safe for patients and staff.

Heroin-assisted treatment (HAT) was introduced in Switzerland in 1994 and comprises the prescription of diacetylmorphine (DAM, he**in) for patients with severe opioid use disorder. Provision of Swiss HAT is limited to specialised treatment centres, ...

04/16/2025

https://authors.elsevier.com/sd/article/S2667193X25001073

"...there is a strong evidence-base supporting co-prescription of opioids and stimulants for patients with co-occurring mental and substance use disorder diagnoses."

02/18/2025

🟢

02/03/2025

https://journals.lww.com/journaladdictionmedicine/fulltext/9900/prescribing_psychostimulants_for_the_treatment_of.440.aspx

"Professional organizations, addiction clinicians, and researchers can reinforce this practice through publishing expert recommendations, developing clinician education materials, and disseminating their real-world experiences and well-documented treatment plans."

t controlled prescription psychostimulants such as dextroamphetamine, methylphenidate, and modafinil are associated with reductions in self-reported stimulant use, craving, and depressive symptoms. Despite this positive initial evidence, prescribing rates of these medications for StUD treatment rema...

01/20/2025

The so-called war on drugs has failed. In the last century, countries have increasingly attempted absolute prohibition of drug use, often via penal measures. Despite global action, these policies have not deterred drug use: we have reached record levels of “abuse, illicit cultivation and productio...